IDWeek 2023

IDWeek 2023
October 11-16, 2023

Infectious Diseases Society of America: ID Week 2023.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (14)

    Increase in New HIV Diagnoses Following Decrease in Use of Pre-Exposure Prophylaxis (PrEP) during The COVID-19 Pandemic

    • Author(s): Tao, L
    • truvada
    • descovy
    • HIV / AIDS
    • Poster

    The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US

    • Author(s): Tao, L
    • descovy
    • truvada
    • HIV / AIDS
    • Poster

    Antiretroviral Treatment (ART) Packaging Preferences and Their Impact on Adherence Among People With HIV (PWH): Findings From a Best-Worst Scaling Survey

    • Author(s): Dunbar, M
    • other
    • HIV / AIDS
    • Poster

    Weight and Metabolic Changes after using Long-Acting Lenacapavir in a Combination Regimen in Treatment Naïve PWH

    • Author(s): Kumar, P
    • sunlenca
    • HIV / AIDS
    • Poster

    Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 104 results

    • Author(s): Ogbuagu, O
    • sunlenca
    • HIV / AIDS
    • Poster

    Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations

    • Author(s): Trottier, B
    • biktarvy
    • HIV / AIDS
    • Poster

    Remdesivir and Obeldesivir Retain Potent Activity Against SARS-COV-2 Omicron Variants

    • Author(s): Rodriguez, L
    • veklury
    • obeldesivir
    • COVID-19
    • Poster

    Resistance Analyses from the Remdesivir Phase 3 REDPINE Study in Participants with Severely Reduced Kidney Function Who Were Hospitalized for COVID-19

    • Author(s): Andreatta, K
    • veklury
    • COVID-19
    • Poster

    Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies

    • Author(s): Force, L
    • obeldesivir
    • COVID-19
    • Poster

    Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir

    • Author(s): Pitts, J
    • obeldesivir
    • COVID-19
    • Poster

    Drug-Drug Interaction Profiling of Obeldesivir; A Promising Oral Treatment for COVID-19

    • Author(s): Amini, E
    • obeldesivir
    • COVID-19
    • Poster

    Clinical Evaluation of Drug-Drug Interactions with Remdesivir

    • Author(s): Peng, C
    • veklury
    • COVID-19
    • Poster

    Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?

    • Author(s): Lat, A
    • sunlenca
    • HIV / AIDS
    • Poster

    Efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG)-based 3-drug regimens in adults with HIV who have suboptimal antiretroviral adherence

    • Author(s): Andreatta, K
    • biktarvy
    • HIV / AIDS
    • Poster